|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Vir Biotechnology, Inc. (VIR) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
127,390,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
10,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$246,341 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
4 |
Total Shares Sold |
167,399 |
167,399 |
965,615 |
6,005,613 |
Total Sell Value |
$1,671,921 |
$1,671,921 |
$22,530,609 |
$153,953,368 |
Total People Sold |
5 |
5 |
9 |
11 |
Total Sell Transactions |
10 |
10 |
26 |
123 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-05-03 |
4 |
AS |
$25.51 |
$2,134,691 |
I/I |
(83,674) |
17,751,051 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-05-01 |
4 |
AS |
$25.30 |
$77,812 |
I/I |
(3,075) |
17,834,725 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-04-25 |
4 |
AS |
$25.30 |
$24,313 |
I/I |
(961) |
17,837,800 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-04-24 |
4 |
AS |
$25.42 |
$1,678,633 |
I/I |
(66,038) |
17,838,761 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-04-21 |
4 |
AS |
$25.76 |
$7,872,247 |
I/I |
(305,393) |
17,904,799 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-04-20 |
4 |
AS |
$25.06 |
$165,147 |
I/I |
(6,590) |
18,210,192 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-04-19 |
4 |
AS |
$25.12 |
$1,911,968 |
I/I |
(76,114) |
18,216,782 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-04-18 |
4 |
AS |
$25.12 |
$174,661 |
I/I |
(6,953) |
18,292,896 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-04-17 |
4 |
AS |
$25.06 |
$263,741 |
I/I |
(10,524) |
18,299,849 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2023-04-14 |
4 |
AS |
$25.11 |
$240,152 |
I/I |
(9,565) |
18,310,373 |
|
- |
|
Lee Sung |
Chief Financial Officer |
|
2023-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
66,500 |
66,500 |
|
- |
|
Sato Vicki L |
Director |
|
2023-03-08 |
4 |
AS |
$22.59 |
$405,062 |
D/D |
(17,935) |
1,327,324 |
|
- |
|
Friedl-Naderer Johanna |
EVP & Chief Operating Officer |
|
2023-03-03 |
4 |
S |
$22.82 |
$33,819 |
D/D |
(1,482) |
148,518 |
|
- |
|
Sigal Charles Elliott |
Director |
|
2023-03-01 |
4 |
AB |
$22.73 |
$56,816 |
I/I |
2,500 |
10,000 |
|
- |
|
Pang Phillip |
Chief Medical Officer |
|
2023-02-27 |
4 |
AS |
$23.00 |
$238,170 |
D/D |
(10,320) |
188,000 |
|
- |
|
Scangos George A |
President and CEO |
|
2023-02-24 |
4 |
AS |
$22.74 |
$352,682 |
D/D |
(15,119) |
168,489 |
|
- |
|
Horn Howard |
CFO |
|
2023-02-23 |
4 |
S |
$25.97 |
$58,387 |
D/D |
(2,248) |
230,712 |
|
- |
|
Hanly Ann M. |
Chief Technology Officer |
|
2023-02-23 |
4 |
S |
$25.97 |
$59,790 |
D/D |
(2,302) |
117,203 |
|
- |
|
Rice Steven J. |
Chief Administrative Officer |
|
2023-02-23 |
4 |
S |
$25.97 |
$46,622 |
D/D |
(1,795) |
108,414 |
|
- |
|
Scangos George A |
President and CEO |
|
2023-02-23 |
4 |
AS |
$25.97 |
$328,065 |
D/D |
(12,631) |
183,608 |
|
- |
|
Pang Phillip |
Chief Medical Officer |
|
2023-02-23 |
4 |
S |
$25.97 |
$74,750 |
D/D |
(2,878) |
198,320 |
|
- |
|
Hanly Ann M. |
Chief Technology Officer |
|
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
119,505 |
|
- |
|
Rice Steven J. |
Chief Administrative Officer |
|
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
73,000 |
110,209 |
|
- |
|
Friedl-Naderer Johanna |
EVP & Chief Operating Officer |
|
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
150,000 |
|
- |
|
Pang Phillip |
Chief Medical Officer |
|
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
201,198 |
|
- |
|
575 Records found
|
|
Page 3 of 23 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|